Novo Nordisk stock holds after Orbis Medicines deal

Published on 09/20/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock closed at USD 43.23 on September 18, 2026, with a USD 193.04 billion market value. MarketBeat shows a hold rating and a USD 64.94 consensus target.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) closed at USD 43.23 on September 18, 2026, with a market capitalization of USD 193.04 billion and a 52-week range of USD 35.12 to USD 64.16. MarketBeat also showed volume of 10.36 million shares and a hold consensus with a USD 64.94 target on September 19, 2026.

Deal talk sets the tone

According to Aktiencheck.de on September 19, 2026, the stock traded at EUR 37.58 after a licensing deal with Orbis Medicines. The same report said the shares were 31 percent below the 52-week high of EUR 54.86.

That move keeps valuation and pipeline news intertwined. For investors, the gap to the yearly high is still the sharpest market marker.

Consensus stays cautious

According to MarketBeat on September 19, 2026, Novo Nordisk carried a hold consensus, 3 buy ratings, 14 hold ratings and 1 sell rating. MarketBeat also listed a consensus target of USD 64.94 and a high target of USD 175.00.

On the operating side, the latest visible report period in the same coverage remains the first half of 2026, with revenue growth and margin development carried into current sentiment. That is where the next debate now sits.

Stock stays under pressure

Novo Nordisk stock ended September 18, 2026 at USD 43.23, and the intraday range on MarketBeat stretched from USD 42.78 to USD 43.54. Volume reached 10.36 million shares, a level that shows how closely traders are still watching the name.